Brief: AC Immune Announces Amendment To Morphomer ® Tau License And Collaboration Agreement With Lilly
07/04/2026 12:13
April 7 (Reuters) - AC Immune SA ACIU.O: AC IMMUNE ANNOUNCES AMENDMENT TO MORPHOMER ® TAU LICENSE AND COLLABORATION AGREEMENT WITH LILLY AC IMMUNE SA - IND-ENABLING STUDIES TO COMMENCE IN H1 2026 AC IMMUNE SA - AMENDED AGREEMENT COVERS DEVELOPMENT OF NEW TAU MORPHOMER CANDIDATES AC IMMUNE SA - UNDER AMENDMENT, CO TO RECEIVE CHF10 MILLION UPFRONT PAYMENT AND PHASE 1 MILESTONE PAYMENT AC IMMUNE SA - ELIGIBLE FOR OVER CHF1.7 BILLION IN MILESTONES PLUS TIERED ROYALTIES Source text: ID:nGNXC8zcd Further company coverage: ACIU.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on AC Immune SA
See all newsBrief: Ac Immune To Receive Research Grant From Goradia Family For Development Of Aci-7104 In Parkinson’S Disease
AC Immune Q1 net loss narrows on lower expenses
Brief: AC Immune Announces Amendment To Morphomer ® Tau License And Collaboration Agreement With Lilly
U.S. STOCKS ON THE MOVE-Darden Restaurants, Mastercard, Accenture
U.S. STOCKS ON THE MOVE-Darden Restaurants, Mastercard, Accenture